BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1854179)

  • 1. Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function.
    Pietroski NA; Graziani AL; Lawson LA; Bland JA; Rogers JD; MacGregor RR
    Antimicrob Agents Chemother; 1991 May; 35(5):972-5. PubMed ID: 1854179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twice daily intramuscular imipenem/cilastatin in the treatment of skin and soft tissue infections.
    Sexton DJ; Wlodaver CG; Tobey LE; Yangco BG; Graziani AL; MacGregor RR
    Chemotherapy; 1991; 37 Suppl 2():26-30. PubMed ID: 1879184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.
    Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
    Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration.
    Alarabi AA; Cars O; Danielson BG; Salmonson T; Wikström B
    J Antimicrob Chemother; 1990 Jul; 26(1):91-8. PubMed ID: 2211452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical pharmacokinetics of an imipenem-cilastatin combination].
    Singlas E
    Presse Med; 1990 Apr; 19(13):598-605. PubMed ID: 2139939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipenem/cilastatin: evolution of the sustained-release intramuscular formulation.
    Kahan FM; Rogers JD
    Chemotherapy; 1991; 37 Suppl 2():21-5. PubMed ID: 1879183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis.
    Chan CY; Lai KN; Lam AW; Li PK; Chung WW; French GL
    J Antimicrob Chemother; 1991 Feb; 27(2):225-32. PubMed ID: 2055813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
    Boucher BA; Hudson JQ; Hill DM; Swanson JM; Wood GC; Laizure SC; Arnold-Ross A; Hu ZY; Hickerson WL
    Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill.
    Hashimoto S; Honda M; Yamaguchi M; Sekimoto M; Tanaka Y
    ASAIO J; 1997; 43(1):84-8. PubMed ID: 9116359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis.
    Bergan T; Michalsen H; Malmborg AS; Pedersen SS; Pressler T; Storrøsten OT; Strandvik B
    Chemotherapy; 1993; 39(6):369-73. PubMed ID: 8222862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants].
    Toyonaga Y; Sugita M; Hori M; Joh K
    Jpn J Antibiot; 1988 Nov; 41(11):1671-91. PubMed ID: 3210301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biliary excretion of imipenem-cilastatin in hospitalized patients.
    Graziani AL; Gibson GA; MacGregor RR
    Antimicrob Agents Chemother; 1987 Nov; 31(11):1718-21. PubMed ID: 3435120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients.
    Kihara M; Ikeda Y; Shibata K; Masumori S; Ebira H; Shiratori K; Ueda S; Takagi N; Umemura S; Shionoiri H
    Clin Nephrol; 1994 Sep; 42(3):193-7. PubMed ID: 7994939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.
    Tegeder I; Bremer F; Oelkers R; Schobel H; Schüttler J; Brune K; Geisslinger G
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2640-5. PubMed ID: 9420033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using imipenem and cilastatin during continuous renal replacement therapy.
    Cotton A; Franklin BD; Brett S; Holmes A
    Pharm World Sci; 2005 Oct; 27(5):371-5. PubMed ID: 16341743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile levels of imipenem in patients with T-drain following the administration of imipenem/cilastatin.
    Mayer M; Tophof C; Opferkuch W
    Infection; 1988; 16(4):225-8. PubMed ID: 3182087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD).
    Vos MC; Vincent HH; Yzerman EP
    Intensive Care Med; 1992; 18(5):282-5. PubMed ID: 1527259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates].
    Azagami S; Kusumoto Y; Oikawa T; Osano M; Shiro H; Shirai Y; Nakamura M
    Jpn J Antibiot; 1988 Nov; 41(11):1704-14. PubMed ID: 3210302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101.
    Norrby SR; Burman LA; Sassella D; Corigli R; Cassinelli G; Franceschi G; Dornbusch K
    J Antimicrob Chemother; 1990 Mar; 25(3):371-83. PubMed ID: 2338416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.